Contact
searchSearch
HMP Global

Pharmacy Learning Network

PharmLaw

PharmLaw
AIDS Healthcare Foundation Settles Medicare Advantage False Claims Allegations
10/07/2026
Grace Taylor, MS, MA
The AIDS Healthcare Foundation has agreed to pay $1.44 million to resolve federal allegations involving unsupported diagnosis codes and Medicare Advantage payments.
The AIDS Healthcare Foundation has agreed to pay $1.44 million to resolve federal allegations involving unsupported diagnosis codes and Medicare Advantage payments.
The AIDS Healthcare Foundation...
10/07/2026
Pharmacy Learning Network
PharmLaw
Florida Attorney General Sues Insulin Manufacturers, PBMs Over Alleged Pricing Scheme
09/30/2026
Grace Taylor, MS, MA
Florida is challenging insulin manufacturer and pharmacy benefit manager (PBM) rebate and formulary arrangements that the state alleges contributed to higher insulin costs and restricted competition.
Florida is challenging insulin manufacturer and pharmacy benefit manager (PBM) rebate and formulary arrangements that the state alleges contributed to higher insulin costs and restricted competition.
Florida is challenging insulin...
09/30/2026
Pharmacy Learning Network
PharmLaw
Express Scripts Faces Lawsuit Over Arkansas Pharmacy Reimbursement Rates
09/23/2026
Grace Taylor, MS, MA
Arkansas pharmacies allege Express Scripts violated state law by reimbursing prescription claims below required rates.
Arkansas pharmacies allege Express Scripts violated state law by reimbursing prescription claims below required rates.
Arkansas pharmacies allege...
09/23/2026
Pharmacy Learning Network
PharmLaw
Dompé to Pay $32 Million Over Patient Assistance Foundation Kickback Allegations
09/16/2026
Hannah Musick
Dompé U.S. has agreed to pay $32 million to resolve allegations involving Medicare copay assistance for Oxervate, highlighting Anti-Kickback Statute compliance risks associated with manufacturer-funded patient assistance programs and the...
Dompé U.S. has agreed to pay $32 million to resolve allegations involving Medicare copay assistance for Oxervate, highlighting Anti-Kickback Statute compliance risks associated with manufacturer-funded patient assistance programs and the...
Dompé U.S. has agreed to pay $32...
09/16/2026
Pharmacy Learning Network
PharmLaw
Florida Alleges Express Scripts, Prime Therapeutics Engaged in PBM Reimbursement Price-Fixing
09/09/2026
Hannah Musick
Florida has sued Express Scripts and Prime Therapeutics over allegations that the pharmacy benefit managers (PBMs) unlawfully coordinated pharmacy reimbursement rates, raising new antitrust and compliance questions surrounding PBM contracting...
Florida has sued Express Scripts and Prime Therapeutics over allegations that the pharmacy benefit managers (PBMs) unlawfully coordinated pharmacy reimbursement rates, raising new antitrust and compliance questions surrounding PBM contracting...
Florida has sued Express Scripts...
09/09/2026
Pharmacy Learning Network

FDA Recalls

News
Estradiol Gel Recalled Due to Defective Container
10/08/2026
Rebecca Amrick
Estradiol gel is under a voluntary Class II recall after defects were discovered in the product’s container, affecting 2592 cartons.
Estradiol gel is under a voluntary Class II recall after defects were discovered in the product’s container, affecting 2592 cartons.
Estradiol gel is under a...
10/08/2026
Pharmacy Learning Network
News
Zoladex (Goserelin) Implant Recalled Due to Improper Temperature Regulation
10/08/2026
Rebecca Amrick
A voluntary Class II recall has been issued for Zoladex (goserelin) implant due to issues in temperature regulation, a discrepancy that affects 296 cartons.
A voluntary Class II recall has been issued for Zoladex (goserelin) implant due to issues in temperature regulation, a discrepancy that affects 296 cartons.
A voluntary Class II recall has...
10/08/2026
Pharmacy Learning Network
News
Ranolazine Tablets Recalled Due to Failed Dissolution Specifications
10/08/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for ranolazine extended-release tablets after the product failed to meet dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for ranolazine extended-release tablets after the product failed to meet dissolution specifications.
The US Food and Drug...
10/08/2026
Pharmacy Learning Network
News
Olanzapine Tablets Recalled Due to Failed Impurities Specifications
10/01/2026
Rebecca Amrick
Olanzapine tablets are under a voluntary Class III recall after the product failed to meet impurities specifications, affecting 22 032 bottles.
Olanzapine tablets are under a voluntary Class III recall after the product failed to meet impurities specifications, affecting 22 032 bottles.
Olanzapine tablets are under a...
10/01/2026
Pharmacy Learning Network
News
Menow Sunscreen Pressed Powder Recalled Due to CGMP Deviations
10/01/2026
Rebecca Amrick
A voluntary Class II recall has been issued for Menow sunscreen pressed powder due to Current Good Manufacturing Practice (CGMP) deviations, a discrepancy that affects 2970 units.
A voluntary Class II recall has been issued for Menow sunscreen pressed powder due to Current Good Manufacturing Practice (CGMP) deviations, a discrepancy that affects 2970 units.
A voluntary Class II recall has...
10/01/2026
Pharmacy Learning Network

In the News

News
Estradiol Gel Recalled Due to Defective Container
10/08/2026
Rebecca Amrick
Estradiol gel is under a voluntary Class II recall after defects were discovered in the product’s container, affecting 2592 cartons.
Estradiol gel is under a voluntary Class II recall after defects were discovered in the product’s container, affecting 2592 cartons.
Estradiol gel is under a...
10/08/2026
Pharmacy Learning Network
News
Zoladex (Goserelin) Implant Recalled Due to Improper Temperature Regulation
10/08/2026
Rebecca Amrick
A voluntary Class II recall has been issued for Zoladex (goserelin) implant due to issues in temperature regulation, a discrepancy that affects 296 cartons.
A voluntary Class II recall has been issued for Zoladex (goserelin) implant due to issues in temperature regulation, a discrepancy that affects 296 cartons.
A voluntary Class II recall has...
10/08/2026
Pharmacy Learning Network
News
Ranolazine Tablets Recalled Due to Failed Dissolution Specifications
10/08/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class II recall for ranolazine extended-release tablets after the product failed to meet dissolution specifications.
The US Food and Drug Administration (FDA) has issued a Class II recall for ranolazine extended-release tablets after the product failed to meet dissolution specifications.
The US Food and Drug...
10/08/2026
Pharmacy Learning Network
PharmLaw
AIDS Healthcare Foundation Settles Medicare Advantage False Claims Allegations
10/07/2026
Grace Taylor, MS, MA
The AIDS Healthcare Foundation has agreed to pay $1.44 million to resolve federal allegations involving unsupported diagnosis codes and Medicare Advantage payments.
The AIDS Healthcare Foundation has agreed to pay $1.44 million to resolve federal allegations involving unsupported diagnosis codes and Medicare Advantage payments.
The AIDS Healthcare Foundation...
10/07/2026
Pharmacy Learning Network
News
Olanzapine Tablets Recalled Due to Failed Impurities Specifications
10/01/2026
Rebecca Amrick
Olanzapine tablets are under a voluntary Class III recall after the product failed to meet impurities specifications, affecting 22 032 bottles.
Olanzapine tablets are under a voluntary Class III recall after the product failed to meet impurities specifications, affecting 22 032 bottles.
Olanzapine tablets are under a...
10/01/2026
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use